Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1996-06-24
1999-12-07
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
536 235, 530350, C12N 1500
Patent
active
059981660
ABSTRACT:
Human CD16-II variants, DNA sequences coding for them, their use in therapy and/or in diagnosis of autoimmune diseases and inflammatory illnesses, as well as pharmaceutical compositions comprising them, are disclosed. The sequence listing for the new polypeptides is provided.
REFERENCES:
Gary A. Peltz et al. "Human EcyRIII: Cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG", Proc. Natl. Acad.Sci.USA, vol. 86, pp. 1013-1017 (1989).
David Simmons et al. "The Fcy receptor of natural killer cells is a phospholipid-linked membrane protein", Nature vol.333, 568-570 Jun. 9, 1988.
Richard G. Hoover et al. "Autoregulatory Circuits in Myeloma", The American Society for Clinical Investigation, Inc. vol.95, Jan. 1995, pp. 241-247.
Christophe Teillaud et al. "Soluble CD16 Binds Peripheral Blood Mononuclear Cells and Inhibits Pokeweed-Mitogen-Induced Responses", Blood, vol.82, No. 10 Nov 15, 1993:pp. 3081-3090.
R. G. M. Bredius et al. Role of neutrophil FcyRIIa (CD32) and FcyRIIIb (CD16) polymorphic forms in phagoctosis of human IgG1-and IgG3-opsonized bacteria and erythrocytes immunology 1994 83 624-630.
Tom W. J. Huizinga et al. "Material Genomic Neutrophil FcRIII Deficiency Leading to Neonatal Isoimune Neutropeina", Blood, vol. 76, No. 10 Nov. 15, 1990 pp.1927-1932.
Lewis L. Lanier et al. "Membrane Anchoring of a Human IgG Fc Receptor (CD16) Determined by a Single Amino Acid", Science, vol. 246 pp.1611-1613 Dec. 22, 1989.
Bernard Scallon et al. "A human immuniglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms", Immunology, vol. 86, pp. 5079-5083, Jul. 1989.
Jeffrey Ravetch et al. "Alternative Membrane Forms of FcyRIII(CD16) On Human Natural Killer Cells and Neutrophils", J. Exp. Med, vol.170: 481-497.
Howard Fleit et al. "A Soluble Form of FcyRIII is Present in Human Serum and Other Body Fluids and is Elevated at Sites of Inflammation", Blood, vol. 79 No. 10 May 15, 1992, pp. 2721-2728.
C. Mathiot et al. "Correlation Between Soluble Serum CD16 (sCD16) Levels and Disease Stage in Patients with Multiple Myeloma", Journal of Clinical Immunology, vol.13 No. 1, 1993 pp. 41-48.
Jan G.J. van de Winkel et al. "Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications", Immunology Today, vol. 14 No. 5 1993 pp. 215-221.
Capel et al., "Heterogeneity of Human IgF Fc Receptors, " Immunomethods, vol. 4, No. 1, pp. 25-34, 1994.
Luo, S., "Reverse Transcription-based Polymerase Chain Reaction Cloning of Fc-gamma-R-III Type II variants: Indicating a Polymorphism of Human CD16-II, " Blood, vol. 86, No. 10 (suppl. 1), Dec. 1-5 1995.
Trounstine et al, International Immunology, 2:303-310 1990.
Farber et al, "Rat CD16 is Defined by a Family of Class III Fcgamma Receptors Requiring Co-Expression of Heteroprotein Subunits"; J. of Immun., 146(12); 4352-4361 (1991).
Hass et al, "Identification of a New Genetic IgG-Fc Receptor Polylmorphism Present of NK Cell and Macrophage FcgammaRIIIA"; BloodB4:184a (1994).
Huizinga et al, "Soluble Fcgamma Receptor III in Human Plasma Originates from Release by Neutrophils"; J. Clin. Invest., 86:416-423 (1990).
Ory, et al, "Characterization of Polymorphic Forms of Fc Receptor III on Human Neutrophils"; J. Clin. Invest., 83:1676-1681 (1989).
Rieger et al., Glossary of Genetics and Cytogenetics, page 17, 1976.
Ayala et al., Modern Genetics, page 45, 1980.
Lazar et al., Molecular and Cellular Biology 8:1247-52, Mar. 1988.
Scallon et al. PNAS 86:5079-83, 1989.
Applied Research Systems ARS Holding N.V.
Hutzell Paula K.
Lazar-Wesley Elaine
LandOfFree
CD16-II variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD16-II variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD16-II variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-822545